The abstract is read at the publisher; the summary is JClub's.
Monoclonal antibodies are highlighted as a novel antimicrobial class that can bypass classical resistance mechanisms and provide prophylactic and therapeutic options against AMR.
- Why it matters: AMR is a major health emergency, with 1.27 million infection-related deaths directly caused in 2019 and projections of up to 10 million lives per year at risk by 2050, especially in low- and middle-income countries.
- What they did: This review synthesizes evidence on monoclonal antibodies, discussing their advantages and limitations, the need for rapid diagnostics for personalized use, and how resistance selection risk and production costs could be managed.
- The result: The work implies mAbs could complement existing antimicrobials while emphasizing diagnostics, strategies to limit resistant strain selection, and efforts to improve global access and equity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.